Literature DB >> 1578493

Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.

A Wissner1, M L Carroll, K E Green, S S Kerwar, W C Pickett, R E Schaub, L W Torley, S Wrenn, C A Kohler.   

Abstract

A series of aryl phosphoglyceride (3, 19-61) and bis-aryl phosphate (67-135) antagonists of platelet activating factor (PAF) were prepared. A group of four bifunctional phosphorus reagents (5a-c and 7) were developed that allowed the preparation of these aryl phosphates in which the position of aromatic substitution can be varied. These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets. Selected compounds were also evaluated for their ability to displace [3H]PAF from its receptor on rabbit platelets. These in vitro data were compared to similar data obtained for a number of known PAF antagonists. The compounds were evaluated in vivo, in both the mouse and rabbit, for their ability to prevent death induced by a lethal challenge of PAF. The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied. Compound 105 (CL 184005) has been selected to undergo further development as a potential therapeutic agent for the treatment of septic shock in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1578493     DOI: 10.1021/jm00087a023

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Platelet-activating factor antagonists.

Authors:  M Koltai; P G Braquet
Journal:  Clin Rev Allergy       Date:  1994

2.  Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2'-deoxyuridine, 5-iodo-3'-fluoro-2',3'-dideoxyuridine, and 3'-fluorothymidine for molecular radiotherapy of cancer: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Yu Kimura; Kotaro Inoue; Elizabeth Mack; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2012-03-08       Impact factor: 7.446

3.  Effect of a series of 1-alkyl ether lipids on inhibition of phospholipase A2 activity and PAF responses.

Authors:  C Kohler; M Carroll; E Tarrant; L Torley; A Wissner
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

4.  Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis.

Authors:  L W Torley; W C Pickett; M L Carroll; C A Kohler; R E Schaub; A Wissner; S Q DeJoy; A L Oronsky; S S Kerwar
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 5.  A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?

Authors:  Vasiliki D Papakonstantinou; Nefeli Lagopati; Effie C Tsilibary; Constantinos A Demopoulos; Athanassios I Philippopoulos
Journal:  Bioinorg Chem Appl       Date:  2017-03-28       Impact factor: 7.778

Review 6.  Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis; Constantinos A Demopoulos
Journal:  Molecules       Date:  2019-12-03       Impact factor: 4.411

7.  Synthesis of 4-thiouridines with prodrug functionalization for RNA metabolic labeling.

Authors:  Sarah Moreno; Melanie Brunner; Isabel Delazer; Dietmar Rieder; Alexandra Lusser; Ronald Micura
Journal:  RSC Chem Biol       Date:  2022-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.